… In this Review, we discuss the emerging non-dopaminergic therapies for PD with a focus
on disease modification and treatment of motor symptoms. We examine pharmacological …

Parkinson’s disease (PD) is a common neurodegenerative disease typified by a movement
disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment …

… The lowest carrier frequency was reported to be 2.3% in Norwegian Parkinson's disease
patients [13]. Notably, there is considerable reduction of penetrance in that only about 10% of …

Parkinson’s disease (PD) is a neurodegenerative disorder pathologically distinguished by
degeneration of dopaminergic neurons in the substantia nigra pars compacta. Muscle rigidity, …

… Food and Drug Administration approved the drug levodopa … identified 47 trials as PD treatment
drugs or therapies. Among them, … Additionally, we discuss the most potent drug or therapy …

… in vitro and in vivo models of neurological disorders, emerged from among the multi-target
bio-… class of natural drugs for the treatment of neurodegenerative diseases. Although there are …

Levodopa is the most effective drug for the treatment of Parkinson’s disease, but its use as
an oral medication is complicated by its erratic absorption, extensive metabolism and short …

… No drug has been approved to prevent neuronal cell loss in patients suffering from
Parkinson's disease (PD) or Alzheimer's disease (AD); despite increased comprehension of the …

… ’s disease and Parkinson’s disease. So far, the findings are exciting and promising. Here,
we delineate the dysfunction of the TFEB-mediated ALP in NDs, and we summarize small …

… drugs concerted during the years, for the management of PD. This assessment targets
predominantly most of the drugs … parkinson disease. Arch Neurol, 2005; 62(8):1290–5. Trost BM. …